{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:06:54Z","timestamp":1761523614612},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.bcp.2009.10.009","type":"journal-article","created":{"date-parts":[[2009,10,28]],"date-time":"2009-10-28T08:17:13Z","timestamp":1256717833000},"page":"688-697","source":"Crossref","is-referenced-by-count":24,"title":["Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia"],"prefix":"10.1016","volume":"79","author":[{"given":"Nicholas J.","family":"Donato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dexing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanshi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Giannola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke F.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"December 15(13)","key":"10.1016\/j.bcp.2009.10.009_bib1","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"issue":"February 19(8)","key":"10.1016\/j.bcp.2009.10.009_bib2","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"issue":"March (Suppl. 2)","key":"10.1016\/j.bcp.2009.10.009_bib3","first-page":"S1","article-title":"First-line management of CML: a state of the art review","volume":"6","author":"Hochhaus","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"June (6)","key":"10.1016\/j.bcp.2009.10.009_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1517\/13543784.17.6.865","article-title":"New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check","volume":"17","author":"O\u2019Hare","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"issue":"October (10)","key":"10.1016\/j.bcp.2009.10.009_bib5","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: the new wave of BCR-ABL inhibitors","volume":"6","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"July 15 (14)","key":"10.1016\/j.bcp.2009.10.009_bib6","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","article-title":"Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia","volume":"14","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.bcp.2009.10.009_bib7","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"issue":"July 16 (5682)","key":"10.1016\/j.bcp.2009.10.009_bib8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"January 15 (2)","key":"10.1016\/j.bcp.2009.10.009_bib9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/0008-5472.CAN-05-2788","article-title":"Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680","volume":"66","author":"Young","year":"2006","journal-title":"Cancer Res"},{"issue":"January 15 (2)","key":"10.1016\/j.bcp.2009.10.009_bib10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"issue":"June 28 (2)","key":"10.1016\/j.bcp.2009.10.009_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.canlet.2006.12.004","article-title":"Structural basis for potent inhibition of the aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680","volume":"251","author":"Cheetham","year":"2007","journal-title":"Cancer Lett"},{"issue":"June (6)","key":"10.1016\/j.bcp.2009.10.009_bib12","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1349-7006.2008.00810.x","article-title":"Activity of a novel aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies","volume":"99","author":"Akahane","year":"2008","journal-title":"Cancer Sci"},{"issue":"March 20 (4)","key":"10.1016\/j.bcp.2009.10.009_bib13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.bbrc.2009.01.141","article-title":"Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells","volume":"380","author":"Okabe","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"August 1 (3)","key":"10.1016\/j.bcp.2009.10.009_bib14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood-2007-10-116376","article-title":"Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate","volume":"112","author":"Dai","year":"2008","journal-title":"Blood"},{"issue":"August 2 (31)","key":"10.1016\/j.bcp.2009.10.009_bib15","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL: KIT, and EGF receptor kinases","volume":"102","author":"Carter","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"March (3)","key":"10.1016\/j.bcp.2009.10.009_bib16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm1003","article-title":"VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo","volume":"10","author":"Harrington","year":"2004","journal-title":"Nat Med"},{"issue":"January 15 (2)","key":"10.1016\/j.bcp.2009.10.009_bib17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"issue":"April 15 (8)","key":"10.1016\/j.bcp.2009.10.009_bib18","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood-2006-02-005579","article-title":"Activation of a novel Bcr\/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells","volume":"109","author":"Bartholomeusz","year":"2007","journal-title":"Blood"},{"issue":"January 15 (2)","key":"10.1016\/j.bcp.2009.10.009_bib19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia","volume":"64","author":"Donato","year":"2004","journal-title":"Cancer Res"},{"issue":"March (3)","key":"10.1016\/j.bcp.2009.10.009_bib20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/(SICI)1097-4652(199603)166:3<618::AID-JCP17>3.0.CO;2-2","article-title":"Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181)","volume":"166","author":"Estrov","year":"1996","journal-title":"J Cell Physiol"},{"issue":"July 2 (13)","key":"10.1016\/j.bcp.2009.10.009_bib21","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"Wu","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"January 28 (4)","key":"10.1016\/j.bcp.2009.10.009_bib22","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1074\/jbc.M402053200","article-title":"Regulation of ultraviolet B-induced phosphorylation of histone H3 at serine 10 by Fyn kinase","volume":"280","author":"He","year":"2005","journal-title":"J Biol Chem"},{"issue":"October 1 (7)","key":"10.1016\/j.bcp.2009.10.009_bib23","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/blood-2008-01-128611","article-title":"Concomitant inhibition of Mdm2-p53 interaction and aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia","volume":"112","author":"Kojima","year":"2008","journal-title":"Blood"},{"issue":"August 1 (15)","key":"10.1016\/j.bcp.2009.10.009_bib24","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.1158\/0008-5472.CAN-05-3353","article-title":"The aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function","volume":"66","author":"Gizatullin","year":"2006","journal-title":"Cancer Res"},{"issue":"April 15 (7)","key":"10.1016\/j.bcp.2009.10.009_bib25","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.yexcr.2009.02.008","article-title":"Short and long-term tumor cell responses to aurora kinase inhibitors","volume":"315","author":"Dreier","year":"2009","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.bcp.2009.10.009_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.pharmtox.48.113006.094723","article-title":"Small-molecule inhibitors of the MDM2-p53 protein\u2013protein interaction to reactivate p53 function: a novel approach for cancer therapy","volume":"49","author":"Shangary","year":"2009","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"July (7)","key":"10.1016\/j.bcp.2009.10.009_bib27","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1124\/dmd.107.018267","article-title":"Metabolism and disposition of dasatinib after oral administration to humans","volume":"36","author":"Christopher","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"August (8)","key":"10.1016\/j.bcp.2009.10.009_bib28","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3324\/haematol.12793","article-title":"Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC\/ABL inhibitor dasatinib","volume":"93","author":"Fabarius","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2009.10.009_bib29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/asheducation-2005.1.188","article-title":"Pathobiology of lymphoid and myeloid blast crisis and management issues","author":"Ilaria","year":"2005","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bcp.2009.10.009_bib30","series-title":"12th Congress of the European Hematology Association","article-title":"Contributions of MK-0457 kinase inhibitory activity to clinical activity","author":"Buser","year":"2007"},{"issue":"November 1 (21)","key":"10.1016\/j.bcp.2009.10.009_bib31","doi-asserted-by":"crossref","first-page":"8998","DOI":"10.1158\/0008-5472.CAN-08-2658","article-title":"Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells","volume":"68","author":"Dar","year":"2008","journal-title":"Cancer Res"},{"issue":"July 17 (31)","key":"10.1016\/j.bcp.2009.10.009_bib32","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1038\/onc.2008.76","article-title":"Aurora-A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice","volume":"27","author":"Zhang","year":"2008","journal-title":"Oncogene"},{"issue":"December 10 (50)","key":"10.1016\/j.bcp.2009.10.009_bib33","doi-asserted-by":"crossref","first-page":"52175","DOI":"10.1074\/jbc.M406802200","article-title":"Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215","volume":"279","author":"Liu","year":"2004","journal-title":"J Biol Chem"},{"issue":"January (1)","key":"10.1016\/j.bcp.2009.10.009_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng1279","article-title":"Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53","volume":"36","author":"Katayama","year":"2004","journal-title":"Nat Genet"},{"issue":"April (4)","key":"10.1016\/j.bcp.2009.10.009_bib35","first-page":"593","article-title":"Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques","volume":"7","author":"Neubauer","year":"1993","journal-title":"Leukemia"},{"issue":"June 1 (11)","key":"10.1016\/j.bcp.2009.10.009_bib36","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"issue":"December 1 (23)","key":"10.1016\/j.bcp.2009.10.009_bib37","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res"},{"issue":"December (12)","key":"10.1016\/j.bcp.2009.10.009_bib38","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1074\/mcp.M400124-MCP200","article-title":"Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors","volume":"3","author":"Wissing","year":"2004","journal-title":"Mol Cell Proteomics"},{"issue":"June 15 (12)","key":"10.1016\/j.bcp.2009.10.009_bib39","first-page":"3127","article-title":"The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells","volume":"60","author":"Dorsey","year":"2000","journal-title":"Cancer Res"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209009034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209009034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T20:25:08Z","timestamp":1544905508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295209009034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0006295209009034"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2009.10.009","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}